eMedicine Specialties > Urology > Cancer, Prostate

Prostate Cancer - Biology, Diagnosis, Pathology, Staging, and Natural History: Multimedia

Author: Dan Theodorescu, MD, PhD, Paul Mellon Professor of Urologic Oncology, Department of Urology, University of Virginia Health Sciences Center
Coauthor(s): Tracey L Krupski, MD, MPH, Assistant Professor, Department of Urology, University of Virginia
Contributor Information and Disclosures

Updated: May 21, 2009

Multimedia

Estimated incidence and mortality from prostate c...
(Enlarge Image)
Media file 1: Estimated incidence and mortality from prostate cancer. Courtesy of the American Cancer Society.
[ CLOSE WINDOW ]
Estimated incidence and mortality from prostate c...

Estimated incidence and mortality from prostate cancer. Courtesy of the American Cancer Society.

Relevant anatomy of the male pelvis and genitouri...
(Enlarge Image)
Media file 2: Relevant anatomy of the male pelvis and genitourinary tract.
[ CLOSE WINDOW ]
Relevant anatomy of the male pelvis and genitouri...

Relevant anatomy of the male pelvis and genitourinary tract.

Transrectal sonogram of the prostate showing a hy...
(Enlarge Image)
Media file 3: Transrectal sonogram of the prostate showing a hypoechoic lesion in the peripheral zone of the gland that is suggestive of cancer.
[ CLOSE WINDOW ]
Transrectal sonogram of the prostate showing a hy...

Transrectal sonogram of the prostate showing a hypoechoic lesion in the peripheral zone of the gland that is suggestive of cancer.

Anterior and posterior bone scans of a patient wi...
(Enlarge Image)
Media file 4: Anterior and posterior bone scans of a patient with prostate cancer, with metastasis to the 12th rib and thoracic spine represented by the increased uptake of isotope.
[ CLOSE WINDOW ]
Anterior and posterior bone scans of a patient wi...

Anterior and posterior bone scans of a patient with prostate cancer, with metastasis to the 12th rib and thoracic spine represented by the increased uptake of isotope.

Histologic scoring system showing the 2 most comm...
(Enlarge Image)
Media file 5: Histologic scoring system showing the 2 most common patterns seen on the biopsy specimen, termed the Gleason score.
[ CLOSE WINDOW ]
Histologic scoring system showing the 2 most comm...

Histologic scoring system showing the 2 most common patterns seen on the biopsy specimen, termed the Gleason score.

More on Prostate Cancer - Biology, Diagnosis, Pathology, Staging, and Natural History

References
Further Reading
[ CLOSE WINDOW ]

References

  1. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. Jan-Feb 1993;2(1):27-32. [Medline].

  2. [Best Evidence] Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. Mar 20 2009;27(9):1502-16. [Medline].

  3. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. Aug 23-30 1995;274(8):626-31. [Medline].

  4. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology. Dec 1990;36(6):493-8. [Medline].

  5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. Jan 27 1994;330(4):242-8. [Medline].

  6. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA. Jun 9 2004;291(22):2713-9. [Medline].

  7. [Best Evidence] U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Aug 5 2008;149(3):185-91. [Medline].

  8. Agency for Healthcare Research and Quality. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. AHRQ: Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9&DocID=79. Accessed January 15, 2009.

  9. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. Jul 1996;156(1):127-32. [Medline].

  10. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. Nov 2001;58(5):723-8. [Medline].

  11. Anastasiadis AG, Sachdev R, Salomon L, Ghafar MA, Stisser BC, Shabsigh R, et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol. Dec 2003;129(12):676-82. [Medline].

  12. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. Jun 1998;62(6):1416-24. [Medline].

  13. Bostwick DG. Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem Suppl. 1992;16H:10-9. [Medline].

  14. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol. Mar 2004;17(3):360-79. [Medline].

  15. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer. Feb 1999;35(2):272-7. [Medline].

  16. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. Sep 1993;150(3):797-802. [Medline].

  17. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA. May 14 1997;277(18):1456-60. [Medline].

  18. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. Apr 22-29 1992;267(16):2215-20. [Medline].

  19. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. May 14 1997;277(18):1452-5. [Medline].

  20. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. Sep 17 2003;95(18):1376-83. [Medline].

  21. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol. Sep 1999;5(3):139-42. [Medline].

  22. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. Jun 16 1999;91(12):1033-9. [Medline].

  23. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. Jun 16 1999;91(12):1025-32. [Medline].

  24. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. Jul 27 2005;294(4):433-9. [Medline].

  25. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol. Feb 2008;49(1):107-20. [Medline].

  26. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. The role of imaging in the oncological prostate. Acta Radiol. Feb/2008;49(1):107-20. [Medline].

  27. Gion M, Mione R, Barioli P, Barichello M, Zattoni F, Prayer-Galetti T. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem. Dec 1998;44(12):2462-70. [Medline].

  28. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. Mar 1992;23(3):273-9. [Medline].

  29. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol. Jul 2002;80(3):119-20. [Medline].

  30. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. Aug 2001;28(3):555-65. [Medline].

  31. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. Mar 7 2001;93(5):388-95. [Medline].

  32. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Hggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. Sep 12 2002;347(11):781-9. [Medline].

  33. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. Jan 1 2000;85(1):60-7. [Medline].

  34. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, et al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology. May 1998;51(5):749-57; discussion 757-8. [Medline].

  35. Iczkowski KA, Chen HM, Yang XJ, Beach RA. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology. Nov 2002;60(5):851-4. [Medline].

  36. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. Jan-Feb 2003;53(1):5-26. [Medline].

  37. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. Jan-Feb 2007;57(1):43-66. [Medline].

  38. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis. Nov 2000;3(3):145-151. [Medline].

  39. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. Mar 3 1999;91(5):414-28. [Medline].

  40. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. Feb 1 1999;38(2):83-91. [Medline].

  41. Langer JE, Rovner ES, Coleman BG, et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol. Jan 1996;155(1):228-31. [Medline].

  42. Lee F, Siders DB, Torp-Pedersen ST, Kirscht JL, McHugh TA, Mitchell AE. Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer. Feb 15 1991;67(4 Suppl):1132-42. [Medline].

  43. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. Apr 28 2007;249(1):30-9. [Medline].

  44. McCahy PJ, Harris CA, Neal DE. Breast and prostate cancer in the relatives of men with prostate cancer. Br J Urol. Oct 1996;78(4):552-6. [Medline].

  45. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. Aug 1 1996;335(5):304-10. [Medline].

  46. Moyad MA. Soy, disease prevention, and prostate cancer. Semin Urol Oncol. May 1999;17(2):97-102. [Medline].

  47. Ndubuisi SC, Kofie VY, Andoh JY, Schwartz FM. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology. Jul 1995;46(1):71-7. [Medline].

  48. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. Apr 29 2000;355(9214):1491-8. [Medline].

  49. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. Jul 24 2003;349(4):335-42. [Medline].

  50. Rodriguez C, Calle EE, Tatham LM, Wingo PA, Miracle-McMahill HL, Thun MJ, et al. Family history of breast cancer as a predictor for fatal prostate cancer. Epidemiology. Sep 1998;9(5):525-9. [Medline].

  51. Ruijter ET, Miller GJ, van de Kaa CA, van Bokhoven A, Bussemakers MJ, Debruyne FM, et al. Molecular analysis of multifocal prostate cancer lesions. J Pathol. Jul 1999;188(3):271-7. [Medline].

  52. Sellers TA, Potter JD, Rich SS, Drinkard CR, Bostick RM, Kushi LH, et al. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst. Dec 21 1994;86(24):1860-5. [Medline].

  53. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res. Dec 15 2005;11(24 Pt 1):8669-73. [Medline].

  54. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. Nov 22 1996;274(5291):1371-4. [Medline].

  55. Stemmermann GN, Nomura AM, Chyou PH, Yatani R. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomarkers Prev. Mar-Apr 1992;1(3):189-93. [Medline].

  56. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. Mar 17 2004;291(11):1325-32. [Medline].

  57. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. Jul 1997;158(1):131-7. [Medline].

  58. Theodorescu D, Frierson HF Jr, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol. May 1999;161(5):1442-8. [Medline].

  59. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. Jul 17 2003;349(3):215-24. [Medline].

  60. Walsh PC, Vaughan ED, Retik AB, Wein A, eds. Campbell's Urology. Vol 3. 7th ed. Philadelphia, Pa: WB Saunders; 1998:2487-656.

  61. Warlick CA, Allaf ME, Carter HB. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol. Jan-Feb 2006;24(1):51-7. [Medline].

  62. Weinrich MC, Jacobsen SJ, Weinrich SP, Moul JW, Oesterling JE, Jacobson D, et al. Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology. Dec 1998;52(6):967-73. [Medline].

  63. Whitmore WF Jr. Expectant management of clinically localized prostatic cancer. Semin Oncol. Oct 1994;21(5):560-8. [Medline].

  64. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. Oct 1998;20(2):175-9. [Medline].

  65. Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. Jul 6 1988;80(9):683-7. [Medline].

  66. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. Oct 1 2005;23(28):6992-8. [Medline].

  67. Zimmerman SM. Factors influencing Hispanic participation in prostate cancer screening. Oncol Nurs Forum. Apr 1997;24(3):499-504. [Medline].

[ CLOSE WINDOW ]

Further Reading

For more information, see Medscape’s Prostate Cancer Resource Center

[ CLOSE WINDOW ]

Keywords

prostate adenocarcinoma, adenocarcinoma of the prostate, prostatic cancer, prostate symptoms, prostate cancer screening, prostate-specific antigen, PSA, benign prostatic hypertrophy, BPH, calculi, prostatic cysts, prostatic tuberculosis, prostatitis, prostate cancer biology, prostate cancer natural history, prostate cancer etiology, prostate cancer staging, TNM staging, Gleason score, PSA score

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Dan Theodorescu, MD, PhD, Paul Mellon Professor of Urologic Oncology, Department of Urology, University of Virginia Health Sciences Center
Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology
Disclosure: Nothing to disclose.

Coauthor(s)

Tracey L Krupski, MD, MPH, Assistant Professor, Department of Urology, University of Virginia
Tracey L Krupski, MD, MPH is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Urological Association, and Society of Women in Urology
Disclosure: Nothing to disclose.

Medical Editor

Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, and Tennessee Medical Association
Disclosure: Lilly Consulting fee Consulting; Astellas Consulting fee Speaking and teaching; Indevus Consulting fee Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Martin I Resnick, MD †, Former Lester Persky Professor and Chair, Department of Urology, Former Professor, Department of Oncology, Case Western Reserve University School of Medicine
Martin I Resnick, MD † is a member of the following medical societies: American College of Surgeons, American Federation for Medical Research, American Institute of Ultrasound in Medicine, American Medical Association, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Society of Andrology, American Surgical Association, American Urological Association, Association for Academic Surgery, Endocrine Society, National Kidney Foundation, Ohio Urological Society, and Pan American Medical Association
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Omeros Corporation Consulting fee Consulting

Chief Editor

Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, and Tennessee Medical Association
Disclosure: Lilly Consulting fee Consulting; Astellas Consulting fee Speaking and teaching; Indevus Consulting fee Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.